This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Han Wha Pharma Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01836172
First received: April 17, 2013
Last updated: August 16, 2016
Last verified: August 2016
  Purpose
The purpose of this study is to evaluate the safety and efficacy of YJP-14 capsules for the treatment of endothelial dysfunction in patients with diabetes mellitus.

Condition Intervention Phase
Diabetic Complication Drug: YJP-14 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Han Wha Pharma Co., Ltd.:

Primary Outcome Measures:
  • Flow-mediated dilation (FMD) [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Flow-mediated dilation (FMD) Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) Systolic and Diastolic Blood Pressure [ Time Frame: 8 weeks ]
  • Homeostasis model assessment-insulin resistance (HOMA-IR) [ Time Frame: 4, 8, 12 weeks ]
  • Systolic and Diastolic Blood Pressure [ Time Frame: 4, 8, 12 weeks ]

Other Outcome Measures:
  • HbA1c Serum lipids (LDL, HDL and TG) [ Time Frame: 12 weeks ]
  • Serum Lipids (LDL, HDL and TG) [ Time Frame: 12 weeks ]

Estimated Enrollment: 136
Study Start Date: April 2013
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo t.i.d.
Placebo t.i.d.
Drug: YJP-14
An 50% ethanolic extract of Lindera obtusiloba stems
Other Name: An 50% ethanolic extract of Lindera obtusiloba stems
Placebo Comparator: YJP-14 25 mg t.i.d.
YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
Drug: YJP-14
An 50% ethanolic extract of Lindera obtusiloba stems
Other Name: An 50% ethanolic extract of Lindera obtusiloba stems
Placebo Comparator: YJP-14 50 mg t.i.d.
YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
Drug: YJP-14
An 50% ethanolic extract of Lindera obtusiloba stems
Other Name: An 50% ethanolic extract of Lindera obtusiloba stems
Placebo Comparator: YJP-14 100 mg t.i.d.
YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.
Drug: YJP-14
An 50% ethanolic extract of Lindera obtusiloba stems
Other Name: An 50% ethanolic extract of Lindera obtusiloba stems

Detailed Description:

The primary purpose of this study is to demonstrate superior effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus indicated as mean change difference of flow-mediated dilation (FMD), compared to placebo group after treatment of 12 weeks.

The secondary purposes of this study are divided into three as follows;

  • Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus indicated as mean change difference of FMD, compared to placebo group after treatment of 8 weeks.
  • Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on insulin resistance in diabetes mellitus indicated as mean change difference of Homeostasis Model Assessment-Insulin Resistance (HOMA-IR), compared to placebo group after treatment of 4, 8 and 12 weeks.
  • Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on mean change difference of blood pressure in diabetes mellitus, compared to placebo group after treatment of 4, 8 and 12 weeks.

The exploratory purposes of this study are divided into two as follows;

  • Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on blood glucose level in diabetes mellitus indicated as mean change difference of HbA1c, compared to placebo group after treatment of 12 weeks.
  • Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on vascular stiffness in diabetes mellitus indicated as mean change difference of blood lipids (LDL, HDL and TG), compared to placebo group after treatment of 12 weeks.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Adult-onset DM (defined as fasting glucose greater than 125 mg/dl or by ongoing treatment with an oral hypoglycemic agent), Endothelial dysfunction: FMD below 6.7%, LDL cholesterol level less than 140 mg/dl, Patients agreed to Informed Consent Form

Exclusion Criteria: (Key exclusion criteria) Uncontrolled arterial hypertension (above 139/90 mmHg) or hypotension (below 80/50 mmHg), Severe diabetic complication: diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic vascular complications

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01836172

Locations
Korea, Republic of
Internal medicine, Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Han Wha Pharma Co., Ltd.
Investigators
Principal Investigator: Byung-Hee Oh, M.D., Ph.D. Seoul National University Hospital
  More Information

Publications:
Responsible Party: Han Wha Pharma Co., Ltd.
ClinicalTrials.gov Identifier: NCT01836172     History of Changes
Other Study ID Numbers: HW2012-YJP002
Study First Received: April 17, 2013
Last Updated: August 16, 2016

Keywords provided by Han Wha Pharma Co., Ltd.:
The treatment of diabetic complication

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Complications
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 16, 2017